The 1 Major Dilemma Pfizer and Moderna Face With COVID Vaccine Trials

1 min read

Even though Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) have won Emergency Use Authorization (EUA) for their respective COVID-19 vaccines, clinical studies of the vaccines are still ongoing. One key issue about these studies came up during the U.S. Food and Drug Administration (FDA) advisory committee review of Moderna’s EUA submission. In this Motley Fool Live video recorded on Dec. 18, 2020, healthcare and cannabis bureau chief Corinne Cardina and Fool.com writer Keith Speights discuss the one major dilemma Moderna and Pfizer face with their COVID-19 vaccine trials.

Continue reading

Leave a Reply

Your email address will not be published.

Previous Story

3 Dividend Stocks That Pay You More Than Pepsi Does

Next Story

This Manufacturer Could Reward Dividend Investors Handsomely in 2021

Latest from Blog